This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Grail's cancer blood test faces high-stakes FDA review medicalxpress.com
- FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance qz.com
- Grail multicancer detection test wins FDA advisers’ backing biopharmadive.com
- Grail’s cancer blood test faces high-stakes FDA review winnipegfreepress.com
- GRAIL's Galleri test wins endorsement from FDA panel seekingalpha.com
